All In Biotech

Drugs by condition

Drugs approved for transthyretin amyloidosis

Brand-name prescription drugs and biologics whose FDA label lists transthyretin amyloidosis as an approved use. Matched on the label phrases: "transthyretin", "ATTR".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

5

Still marketed, NDA or BLA

Drug classes

2

Novel drugs

4

New molecular entities and new biologics

In development

3

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for transthyretin amyloidosis.

  • Attruby (Acoramidis Hydrochloride) · Bridgebio Pharma NovelOrphanNov 22, 2024
  • Wainua (Autoinjector) (Eplontersen Sodium) · Astrazeneca Ab NovelOrphanDec 21, 2023
  • Amvuttra (Vutrisiran Sodium) · Alnylam Pharms INC NovelOrphanJun 13, 2022
  • Vyndamax (Tafamidis) · Foldrx Pharms OrphanMay 3, 2019
  • Onpattro (Patisiran Sodium) · Alnylam Pharms INC NovelBreakthrough therapyPriority reviewOrphanAug 10, 2018

All approved drugs for transthyretin amyloidosis, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Transthyretin-directed RNA Interaction (1)

Class not listed in FDA's data (4)

  • Attruby Acoramidis Hydrochloride · Bridgebio Pharma · 2024
  • Amvuttra Vutrisiran Sodium · Alnylam Pharms INC · 2022
  • Onpattro Patisiran Sodium · Alnylam Pharms INC · 2018
  • Vyndamax Tafamidis · Foldrx Pharms · 2019

Drugs in development for transthyretin amyloidosis

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • ALXN2220Phase 34 trials

    AstraZeneca · Transthyretin Amyloid Cardiomyopathy (ATTR-CM), Transthyretin Amyloid Cardiomyopathy, Amyloid Transthyretin Cardiomyopathy

  • NNC6019-0001Phase 33 trials

    Novo Nordisk · Transthyretin Amyloid Cardiomyopathy (ATTR CM)

  • NucresiranALN-TTRSC04Phase 32 trials

    Alnylam Pharmaceuticals · Transthyretin Amyloidosis With Cardiomyopathy, Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN

1 discontinued brand-name drugs whose label still names it

More on transthyretin amyloidosis: recruiting trials · published research

Related in rare and genetic disease: Hereditary angioedema · Fabry disease · Gaucher disease · Pompe disease · Phenylketonuria (PKU) · Achondroplasia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.